ABSTRACT
Objective: To determine post-discharge mortality and associated factors of the first-wave multicenter Turkish Thoracic Society (TTD)-TURCOVID study.
ABSTRACT
Objective: To evaluate long-term effects of COVID-19, and to determine the risk factors in long-COVID in a cohort of the Turkish Thoracic Society (TTS)-TURCOVID multicenter registry. Method(s): Thirteen centers participated with 831 patients;504 patients were enrolled after exclusions. The study was designed in three-steps: (1) Phone questionnaire;(2) retrospective evaluation of the medical records;(3) face-to-face visit. Result(s): In the first step, 93.5% of the patients were hospitalized;61.7% had a history of pneumonia at the time of diagnosis. A total of 27.1% reported clinical symptoms at the end of the first year. Dyspnea (17.00%), fatigue (6.30%), and weakness (5.00%) were the most prevalent long-term symptoms. The incidence of long-term symptoms was increased by 2.91 fold (95% CI 1.04-8.13, P=0.041) in the presence of chronic obstructive pulmonary disease and by 1.84 fold (95% CI 1.10-3.10, P=0.021) in the presence of pneumonia at initial diagnosis, 3.92 fold (95% Cl 2.29-6.72, P=0.001) of dyspnea and 1.69 fold (95% Cl 1.02-2.80, P=0.040) fatigue persists in the early-post-treatment period and 2.88 fold (95% Cl 1.52-5.46, P=0.001) in the presence of emergency service admission in the post COVID period. In step 2, retrospective analysis of 231 patients revealed that 1.4% of the chest X-rays had not significantly improved at the end of the first year, while computed tomography (CT) scan detected fibrosis in 3.4%. In step 3, 138 (27.4%) patients admitted to face-to-face visit at the end of first year;at least one symptom persisted in 49.27% patients. The most common symptoms were dyspnea (27.60%), psychiatric symptoms (18.10%), and fatigue (17.40%). Thorax CT revealed fibrosis in 2.4% patients. Conclusion(s): COVID-19 symptoms can last for extended lengths of time, and severity of the disease as well as the presence of comorbidities might contribute to increased risk. Long-term clinical issues should be regularly evaluated after COVID-19. Copyright © 2022 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer Medknow.
ABSTRACT
Introduction: As the pandemic continues, SARS-CoV-2 infection has inevitably been detected in patients hospitalized for other reasons. Detection of SARS-CoV-2 infected cases after hospitalization may lead to delay in taking appropriate infection control measures. Materials and Methods: The present study retrospectively scanned all electronic and hard copy records of the cases presented to the hospital and hospitalized for other reasons and then diagnosed as COV1D-19 in Suleyman Demirel University Faculty of Medicine, Research and Training Hospital between 01 April 2020 and 31 December 2020. Results: Accordingly, 22 cases were decided as community-acquired, 3 cases as probable community-acquired, 5 cases as hospital-acquired, and 4 cases as probable hospital-acquired. The reason for sampling for SARS-CoV-2 was determined as having symptoms compatible with COVID-19 in 23 (67.6%) of 34 cases, preoperative screening of COVID-19 infection in 9 (26.5%), and high risky contact in 2 cases (5.9%). Considering contact histories epidemiologically, it was thought that transmission occurred to 8 healthcare staff from 2 cases, and to other patients or relatives from 8 cases, but sequence analysis could not be performed. Conclusion: The high number of hospitalized patients diagnosed as COVID-19 creates a significant burden on the healthcare system in terms of infrastructure and management capacity. It is recommended that patients and healthcare professionals be screened widely and thoroughly, especially in conditions where COVID-19 cases are detected in non-COVID-1 9 units. This kind of screening will allow the potential outbreak to be controlled.
ABSTRACT
After emerging in Wuhan city in December 2019, the coronavirus disease 2019 (COVID-19) rapidly spread throughout China. Although high rates of hospitalization are seen with COVID-19, no specific treatment has been reported, and the choice of antiviral therapies is limited. Favipiravir, approved in Japan for influenza, is one of the drugs that targets RNA-dependent RNA polymerase (RdRP). It significantly decreases the duration of fever, cough dyspnea, and the need of oxygen therapy or noninvasive mechanical ventilation, especially in moderate COVID-19 cases. In the current paper we presented four cases with worsening clinical conditions and the development of hypoxia who were treated with Favipiravir before being admitted to the intensive care unit, and who recovered from the disease.